Assess whether to resubmit, meet, or pause the program after an FAERS cluster

SITUATION Regulatory-affairs lead must settle whether to resubmit, meet, or pause the program because an FAERS cluster in a demographic the trials under-enrolled hit a mid-size sponsor after a complete response letter. The evidence on hand is inspection-readiness findings at a CMO; name the Pharma & Life Sciences option that file actually supports.

DECISION Regulatory-affairs lead in a mid-size sponsor after a complete response letter must choose To resubmit, meet, / Pause the program using inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled.

HYPOTHESES TO TEST 1. An FAERS cluster in a demographic the trials under-enrolled is noise around an already-controlled FDA Response and Labeling process in a mid-size sponsor after a complete response letter, given inspection-readiness findings at a CMO. 2. An FAERS cluster in a demographic the trials under-enrolled is the event in inspection-readiness findings at a CMO that forces To resubmit, meet, for regulatory-affairs lead under Pharma & Life Sciences. 3. Inspection-readiness findings at a CMO shows a one-file miss after an FAERS cluster in a demographic the trials under-enrolled, not a FDA Response and Labeling program failure. 4. Inspection-readiness findings at a CMO cannot decide to resubmit, meet, or yet after an FAERS cluster in a demographic the trials under-enrolled; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

ANALYSIS REQUIRED 1. Check whether inspection-readiness findings at a CMO supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a mid-size sponsor after a complete response letter. 3. Trace CMC, labeling, or pharmacovigilance facts in inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read inspection-readiness findings at a CMO against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move to resubmit, meet, or for regulatory-affairs lead.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / FDA Response and Labeling packet (inspection-readiness findings at a CMO after an FAERS cluster in a demographic the trials under-enrolled). If inspection-readiness findings at a CMO cannot force a Pharma & Life Sciences label under FDA Response and Labeling, stop. Do not invent missing evidence a mid-size sponsor after a complete response letter does not have.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in inspection-readiness findings at a CMO, then the action for regulatory-affairs lead - Hypothesis scorecard against inspection-readiness findings at a CMO: supported / rejected / untestable - What changes to resubmit, meet, or if an FAERS cluster in a demographic the trials under-enrolled is later withdrawn - Named option among To resubmit, meet,, Pause the program and the fact that kills the others